146 related articles for article (PubMed ID: 21809995)
1. The oncofetal protein IMP3: a novel molecular marker to predict aggressive meningioma.
Hao S; Smith TW; Chu PG; Liu Q; Ok CY; Woda BA; Lu D; Lin P; Wang SA; Dresser K; Rock KL; Jiang Z
Arch Pathol Lab Med; 2011 Aug; 135(8):1032-6. PubMed ID: 21809995
[TBL] [Abstract][Full Text] [Related]
2. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder.
Sitnikova L; Mendese G; Liu Q; Woda BA; Lu D; Dresser K; Mohanty S; Rock KL; Jiang Z
Clin Cancer Res; 2008 Mar; 14(6):1701-6. PubMed ID: 18347170
[TBL] [Abstract][Full Text] [Related]
3. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.
Jiang Z; Chu PG; Woda BA; Rock KL; Liu Q; Hsieh CC; Li C; Chen W; Duan HO; McDougal S; Wu CL
Lancet Oncol; 2006 Jul; 7(7):556-64. PubMed ID: 16814207
[TBL] [Abstract][Full Text] [Related]
4. Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas.
Cai Z; Zhang C; Zou Y; Lu C; Hu H; Qian J; Jiang L; Hu G
Int J Clin Oncol; 2017 Aug; 22(4):660-666. PubMed ID: 28243945
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for patients with World Health Organization grade III meningiomas treated at a single center.
Shan B; Zhang J; Song Y; Xu J
Medicine (Baltimore); 2017 Jun; 96(26):e7385. PubMed ID: 28658170
[TBL] [Abstract][Full Text] [Related]
6. Association between laminin γ1 expression and meningioma grade, recurrence, and progression-free survival.
Ke HL; Ke RH; Li B; Wang XH; Wang YN; Wang XQ
Acta Neurochir (Wien); 2013 Jan; 155(1):165-71. PubMed ID: 23053286
[TBL] [Abstract][Full Text] [Related]
7. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.
Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z
Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661
[TBL] [Abstract][Full Text] [Related]
8. IMP3 expression in small-intestine neuroendocrine neoplasms: a new predictor of recurrence.
Massironi S; Del Gobbo A; Cavalcoli F; Fiori S; Conte D; Pellegrinelli A; Milione M; Ferrero S
Endocrine; 2017 Nov; 58(2):360-367. PubMed ID: 28210937
[TBL] [Abstract][Full Text] [Related]
9. A study of UbcH10 expression and its association with recurrence of meningiomas.
Jiang L; Wang T; Bao Y; Qian J; Wu XJ; Hu GH; Lu YC
J Surg Oncol; 2012 Sep; 106(3):327-31. PubMed ID: 22095464
[TBL] [Abstract][Full Text] [Related]
10. Low Transforming Growth Factor-β3 Expression Predicts Tumor Malignancy in Meningiomas.
Ma J; Li D; Chen Y; Zhang Y; Song L; Tian K; Yang Y; Chen L; Weng J; Cao X; Hao S; Wang L; Wu Z; Zhang J
World Neurosurg; 2019 May; 125():e353-e360. PubMed ID: 30703597
[TBL] [Abstract][Full Text] [Related]
11. Expression of p40 (∆Np63) protein in meningiomas, an unexpected finding: immunohistochemical study and evaluation of its possible prognostic role.
Guadagno E; Del Basso De Caro M; Pignatiello S; Sciammarella C; Solari D; Cappabianca P; Maiuri F; Dones F
J Neurooncol; 2016 Sep; 129(3):405-413. PubMed ID: 27394131
[TBL] [Abstract][Full Text] [Related]
12. The oncofetal protein IMP3: a novel grading tool and predictor of poor clinical outcome in human gliomas.
Del Gobbo A; Vaira V; Ferrari L; Patriarca C; Di Cristofori A; Ricca D; Caroli M; Rampini P; Bosari S; Ferrero S
Biomed Res Int; 2015; 2015():413897. PubMed ID: 25695077
[TBL] [Abstract][Full Text] [Related]
13. MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.
Winther TL; Torp SH
J Neurooncol; 2017 Feb; 131(3):575-583. PubMed ID: 27868157
[TBL] [Abstract][Full Text] [Related]
14. p-CREB expression in human meningiomas: correlation with angiogenesis and recurrence risk.
Barresi V; Branca G; Caffo M; Tuccari G
J Neurooncol; 2015 Mar; 122(1):87-95. PubMed ID: 25563814
[TBL] [Abstract][Full Text] [Related]
15. Surgery for convexity meningioma: Simpson Grade I resection as the goal: clinical article.
Hasseleid BF; Meling TR; Rønning P; Scheie D; Helseth E
J Neurosurg; 2012 Dec; 117(6):999-1006. PubMed ID: 23061394
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of EGFR expression in de novo and progressed atypical and anaplastic meningiomas: an immunohistochemical and fluorescence in situ hybridization pilot study.
Caltabiano R; Barbagallo GM; Castaing M; Cassenti A; Senetta R; Cassoni P; Albanese V; Lanzafame S
J Neurosurg Sci; 2013 Jun; 57(2):139-51. PubMed ID: 23486338
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
Chromecki TF; Cha EK; Pummer K; Scherr DS; Tewari AK; Sun M; Fajkovic H; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
BJU Int; 2012 Jul; 110(1):63-8. PubMed ID: 22077633
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
19. RNA-binding protein insulin-like growth factor II mRNA-binding protein 3 expression promotes tumor invasion and predicts early recurrence and poor prognosis in hepatocellular carcinoma.
Jeng YM; Chang CC; Hu FC; Chou HY; Kao HL; Wang TH; Hsu HC
Hepatology; 2008 Oct; 48(4):1118-27. PubMed ID: 18802962
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
